HEALTHEQUITY INC

HealthEquity insider Dillion Adrian T buys 7,632 shares at $32.50 while selling 7,932 shares—showing disciplined confidence in long‑term growth despite sector volatility.

HealthEquity insider selling by EVP Fiore Henry shows routine 10b5‑1 plan trades, not a bearish signal – stay updated on its impact.

HealthEquity insider sale: Gathright sells 2,270 shares at $93.07—routine “sell‑to‑cover” amid rising platform earnings. Discover what this means for investors.

HealthEquity insider selling: EVP Michael Fiore’s recent 3,142‑share sale signals steady executive divestment, yet the company’s fundamentals and growth outlook remain intact.

HealthEquity insider activity: EVP Rajasekar Sunil holds RSUs while top execs sell – a contrast that signals confidence in future growth and potential market impact.

HealthEquity’s CTO exit sparks insider selling and investor uncertainty: analyze the impact on tech strategy, share price, and future growth.

HealthEquity CEO Cutler Scott sells 4,931 shares on a quiet day—no distress, just routine liquidity amid a CTO change.

HealthEquity insider sale: founder sells 2,559 shares amid CTO exit, but long‑term stake stays strong—insider activity, tech shift, and market reaction explained.

Delano’s March 31 HealthEquity share sale shows disciplined short‑term liquidity tactics amid steady fundamentals, reassuring investors that management remains confident in the company’s growth.

HealthEquity insider sale: founder Stephen Neeleman sold 9,292 shares at $82.53 – a routine move that signals long‑term confidence amid strong fundamentals and a growing health‑savings platform.